Biomea Fusion Stock (NASDAQ:BMEA)

Forecast Ownership Financials Chart

Previous Close

$1.75

52W Range

$1.53 - $13.43

50D Avg

$2.81

200D Avg

$5.79

Market Cap

$60.87M

Avg Vol (3M)

$628.08K

Beta

-0.09

Div Yield

-

BMEA Company Profile

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

106

IPO Date

Apr 16, 2021

Website

BMEA Performance

BMEA Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-144.07M	$-126.14M	$-83.63M
Net Income	$-138.43M	$-117.25M	$-80.02M
EBITDA	$-144.07M	$-124.62M	$-82.94M
Basic EPS	$-3.83	$-3.44	$-2.73
Diluted EPS	$-3.83	$-3.44	$-2.73

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
DSGN	Design Therapeutics, Inc.
HOWL	Werewolf Therapeutics, Inc.
EWTX	Edgewise Therapeutics, Inc.
CGEM	Cullinan Oncology, Inc.
IKNA	Ikena Oncology, Inc.